Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 140

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 140
---
 scientifically validated wellness solutions by developing nutritional products that support
both longevity and health span. Positioned within a rapidly growing global industry expected to reach $8 trillion by 2030, Nugevia products
will leverage Jupiter’s proprietary JOTROL technology, a resveratrol-based platform shown to deliver a nine-fold
increase in bioavailability.

The
first products under the Nugevia brand, focusing on longevity and healthspan, are available for sale and shipments are expected in the
fourth quarter of 2025 through a direct-to-consumer (“DTC”) model. The products are:

| ● | Nugevia GLO (“GLO”), which promotes cellular defense 
 and skin vitality from the inside out;               |

| ● | Nugevia MND (“MND”), which supports cognitive resilience; 
 and                                                       |

| ● | Nugevia PWR (“PWR”), which helps replenish mitochondrial       
 function, which is a key for sustained growth and performance. |

The
three debut formulations—GLO, MND, and PWR—are designed to support cellular resilience through intelligent stacking of synergistic
ingredients, all enhanced for optimal absorption via the JOTROL system.

The
Company plans to market these products in the U.S. and internationally.

Nugevia’s
launch is a pivotal move to monetize Jupiter’s proprietary science, support ongoing clinical trials, and capture a share of the
booming longevity market.

The Company operates through
two segments: (i) the sale of premium nutritional supplements under the Nugevia brand, and (ii) pharmaceutical operations centered on
the development of drug candidates.

Resveratrol

Resveratrol has been studied
for over 50 years by academic institutions as well as by small and large pharmaceutical companies. The multi-functional mechanisms of
resveratrol are well documented in over 20,000 scientific publications. Several of these publications, including a summary paper by AY
Berman et al, published in Precision Oncology 2017, point to the issue of the poor bioavailability that has stopped medical utilization
of regular resveratrol and never received regulatory approval for any indication. We believe the Phase I study we have conducted indicates
that we have resolved the poor bioavailability issue with JOTROL™.

Based upon available scientific
literature, it appears that resveratrol is an activator of SIRT1, one of the mammalian forms of the sirtuin family of proteins. SIRT1
de